GREEN ANDREW M sold $911K of AORT

GREEN ANDREW M (SVP, Regulatory and Quality) sold 44,001 shares of ARTIVION, INC. (AORT) at an average of $20.70 ($20.69–$20.71, $0.91M total) across 2 trades on 2026-06-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · GREEN ANDREW M
Published Jun 15, 2026, 3:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 3:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AORT
Neutral
high confidence
Mentioned
$AORT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AORTNeutralLow
01

Why it matters

The newest fact is the officer’s open-market sale size, price range, and confirmation of a pre-arranged 10b5-1 plan; there is no stated business development or financial update.

02

Market read

Traders may note the insider sale for sentiment, but the 10b5-1 structure and lack of fundamental catalysts keep impact modest.

03

What to watch

The article provides only the sale details; it does not include any offsetting insider buys, changes in guidance, or company-specific news that would contextualize the sale.

Relevance 4/10Novelty 5/10Timing: Filed 2026-06-15; sale executed 2026-06-11.

Background

The article is an SEC Form 4 insider transaction disclosure for Artivion, Inc. (AORT).

Company-level read

Ticker impact

$AORTNeutralHigh confidence
Context

Artivion (AORT) disclosed an SVP regulatory/quality insider open-market sale of 44,001 shares at ~$20.70 via a Form 4.

Expected impact

Likely limited immediate price impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

The filing is a routine Form 4 open-market sale by an officer under a pre-arranged 10b5-1 plan, with no accompanying operational or financial catalyst stated.

Market effects

No sector-level implications; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as a mild negative signal about near-term risk or liquidity needs.

Key entities

  • ARTIVION, INC.

    Subject of the Form 4 insider transaction disclosure.

  • GREEN ANDREW M

    SVP, Regulatory and Quality who sold 44,001 shares under an open-market sale (10b5-1 plan).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AORTMedAI 8/10

Artivion Inc (AORT) (Q3 2026) Earnings Call Highlights: Stent Graft Momentum and Nexus

Artivion Inc. reported Q3 2026 earnings, highlighting a gross margin decline to 61.4% due to mix, ramp costs, and charges. CEO Pat Mackin expects a gradual Nexus U.S. launch in 2027. Onyx growth slowed to 13%, with mid-teens full-year growth expected. The company aims to reduce leverage through EBITDA growth, with free cash flow positive in 2027. Core stent graft growth dipped below mid-teens, but is seen as a solid double-digit business.

$AORTHighAI 8/10

Artivion (AORT) Q3 2026 Earnings Call Transcript

Artivion (AORT) reported Q3 2026 revenue of $123.8M, up 9% YoY. Stent graft revenues grew 12%, On-X grew 13%, while tissue processing and BioGlue saw slight declines. Adjusted EBITDA decreased 8% to $22.5M. The company expects U.S. commercial launch of NEXUS in early 2027 and FDA approval for ARCEVO LSA in 2029, unlocking an $80M opportunity. Gross margins fell to 61.4% due to mix and manufacturing investments. Free cash flow was negative $17.6M.

$AORTMed

Artivion: Q3 Earnings Snapshot

Artivion, Inc. (AORT) reported a Q3 loss of $7.9 million, down from a profit last year. Adjusted EPS was 8 cents. Revenue was $123.8 million. The company expects Q4 revenue between $484M and $492M. Shares have fallen 45% YTD and 46% over 12 months.

$AORTMed

Artivion Reports Third Quarter 2026 Financial Results

ARTIVION, INC. (AORT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston Executive Vice President, Phone: 332-895-3222 Chief Operating Officer & investors@artivion.com Chief Financial Officer Phone: 770-419-3355 Artivion Reports Third Quarter 2026 F

$AORTMed

Artivion Reports Third Quarter 2026 Financial Results

Artivion reported Q3 2026 revenue of $123.8M, up 9% YoY, with a net loss of $7.9M. Adjusted EBITDA declined 8% to $22.5M. CEO Pat Mackin highlighted growth in On-X and stent grafts, and progress in product launches. The company narrowed its 2026 revenue outlook to $484M-$492M, with adjusted EBITDA expected between $93M-$98M.